Latest Funding News

Aurum Resources reports strong high-grade drilling results at its Boundiali and Napié gold projects, backed by a $35.6 million strategic placement to fund resource expansion and feasibility studies.

Vulcan Energy has won up to €104 million in grants from German federal and state governments to advance its sustainable lithium production project, bolstering Europe’s electric vehicle battery supply chain.

Nordic Resources has completed a major acquisition of three advanced gold projects in Finland, lifting its total gold equivalent resources to 1.23 million ounces. The company also secured A$3.5 million in institutional funding and appointed a seasoned mining executive as Chairman.

Polymetals Resources has updated its June 2025 quarterly cash flow report, confirming nearly two quarters of funding and ongoing revenue from concentrate sales. The company’s financing position remains stable amid planned equity issuance.

Bod Science reports a solid net cash inflow of $858,000 in Q4 FY2025, driven by R&D incentives and Biortica funding, while awaiting shareholder approval to complete a key acquisition.

Bod Science Limited reports a positive cash flow quarter driven by customer receipts, an R&D tax incentive, and proceeds from intellectual property sales, while navigating its Deed of Company Arrangement.

Southern Hemisphere Mining has secured a $13 million farm-in deal with FMR Resources to drill its highly prospective Curiosity copper-gold target in Chile, while also expanding its footprint with new exploration licenses in Western Australia.

Prodigy Gold NL has lodged a replacement Appendix 3Y to amend the reported securities held by Managing Director Mark Edwards following his participation in the company’s recent Entitlement Offer.

Norwest Minerals has reported a substantial 33% increase in its Bulgera Gold Project resource to 288,400 ounces and secured $4.85 million to advance exploration, including a new drilling campaign targeting deeper gold zones.

Inhalerx Limited has drawn $247,000 from a $38.5 million funding facility to advance clinical trials for its IRX-211 and IRX-616a drug candidates, reporting positive operating cash flow for the quarter ending June 2025.

InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.

Global Masters Fund Limited has released its quarterly update confirming stable convertible note conversions and a low loan-to-value ratio, underscoring its solid financial footing as of June 2025.